Efficacy of naltrexone and bupropion combination in patients with binge eating disorder: a systematic review and meta-analysis
Authors:
Open Access
- 26 September 2025
- journal article
- review article
- Published by Springer Nature in Eating and Weight Disorders - Studies on Anorexia, Bulimia and Obesity
- Vol. 30 (1) , 1-10
Abstract
Purpose Binge Eating Disorder (BED) is a prevalent condition with limited evidence-based treatments. Naltrexone and Bupropion Combination (NB) targets neurobiological pathways implicated in BED. The Objective of this paper is to evaluate the efficacy of NB for BED in adults through a systematic review and meta-analysis. Methods Following PRISMA guidelines, we searched major databases and trial registries (up to Feb 2025) for randomized controlled trials (RCTs) comparing NB to placebo or usual care in adults with BED. The primary outcome was binge eating frequency; secondary outcomes included weight loss and BMI. Risk of bias (ROB2) and certainty of evidence (GRADE) were assessed. A fixed-effects meta-analysis was performed. Results Four RCTs (n = 444 participants) met inclusion criteria. Meta-analysis of three studies indicated NB did not significantly reduce binge eating frequency compared to controls (Mean Difference [MD] − 1.49, 95% CI − 3.63 to 0.64, p = 0.17). However, NB significantly reduced weight (MD -3.57 kg, 95% CI − 4.86 to − 2.27, p < 0.001) and BMI (MD − 1.24 kg/m2, 95% CI − 1.79 to − 0.70, p < 0.001). The certainty of evidence was assessed as moderate for binge frequency and low for weight and BMI outcomes. Conclusion NB aids weight reduction in adults with BED, but current evidence is insufficient to confirm its efficacy for reducing binge eating frequency. Further high-quality RCTs are warranted. Level of evidence Level I, systematic reviews and meta-analyses.Keywords
This publication has 22 references indexed in Scilit:
- Lifestyle behavioral weight‐loss treatment for binge‐eating disorder in patients with obesity: where's the harm?Obesity, 2025
- Efficacy of opioid antagonist in patients with binge eating behavior: A systemic review and meta-analysisNeuroscience & Biobehavioral Reviews, 2025
- Treatment of Binge-Eating Disorder Across the Lifespan: An Updated Review of the Literature and Considerations for Future ResearchCurrent Obesity Reports, 2024
- Naltrexone/bupropion for binge‐eating disorder: A randomized, double‐blind, placebo‐controlled trialObesity, 2023
- Naltrexone plus bupropion combination medication maintenance treatment for binge-eating disorder following successful acute treatments: randomized double-blind placebo-controlled trialPsychological Medicine, 2023
- Genetics and neurobiology of eating disordersNature Neuroscience, 2022
- Binge eating disorderNature Reviews Disease Primers, 2022
- Quality of life, binge eating and sexual function in participants treated for obesity with sustained release naltrexone/bupropionObesity Science & Practice, 2018
- Naltrexone/bupropion for obesity: An investigational combination pharmacotherapy for weight lossPharmacological Research, 2014
- Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trialThe Lancet, 2010